Editorial

From Heart to Brain: The Next Frontier of Medicine

There is something quietly poetic about the way a journal finds its own rhythm. For four consecutive issues across the entirety of 2025, the cover of the Pacific Journal of Medical and Health Sciences carried a single, commanding image: a 'Golden Anatomical Heart', its coronary vessels gleaming, its chambers luminous against a deep black background. It was not an arbitrary choice. It was a declaration of intent. Volume 10 was a “Year of the Heart”, a year in which this journal turned its sustained attention to the frontiers of cardiovascular medicine, metabolic science, diabetes therapeutics, and endocrine innovation. Across four issues, we charted the emergence of GLP-1 receptor agonists as cardiovascular agents, the precision of factor XIa inhibition in stroke prevention, the revolution of CRISPR-based lipid control, and the extraordinary potential of AI-driven cardiac diagnostics. The Golden Heart served its purpose magnificently.

And yet, as 2025 drew to a close and preparations began for Volume 11, it became clear that medicine itself was signalling a shift. Not a departure from the cardiovascular frontier, which remains as urgent and as fertile as it has ever been, but an expansion. The future of medicine increasingly depends on recognising that organs do not function in isolation but as interconnected systems governed by complex biological communication networks. An upward movement. A migration of the spotlight, with all its attendant intensity and expectation, from the chest to the cranium. From the myocardium to the neuron. From the rhythmic contraction of cardiac muscle to the electrochemical precision of the synaptic impulse. The 'Golden Heart' gave way to the 'Golden Brain'. And in that transition, the Pacific Journal of Medical and Health Sciences finds itself, as it always has, at the intersection of science and the human story.

The Brain: An Organ Unlike Any Other

To speak of the brain as simply an organ is to commit a magnificent understatement. It is, by any measure, the most complex structure in the known biological world. One hundred billion neurons, each forming an average of seven thousand synaptic connections with neighbouring cells, generate a network of extraordinary complexity. The human connectome, if laid end to end, would stretch approximately 150,000 kilometres. The cerebral cortex alone contains roughly sixteen billion neurons arranged in six distinct laminar layers, each with precise connectivity patterns that subserve specific cognitive, motor, sensory, and emotional functions. And yet, for all its complexity, it weighs less than one and a half kilograms and consumes approximately twenty percent of the body's total energy supply while representing only two percent of its mass.

What makes the brain the next great frontier of medicine is not merely its structural complexity, remarkable as that is. It is the convergence of three simultaneous forces: a global epidemic of neurological and neuropsychiatric disease of staggering proportions; a revolution in our understanding of brain biology that is rendering decades of received wisdom obsolete; and the emergence of transformative technologies, from artificial intelligence to optogenetics to closed-loop neural prosthetics, that are making it possible to observe, interact with, and ultimately treat the brain in ways that were unimaginable even a decade ago. These three forces are converging simultaneously, and the clinical and scientific consequences are already reshaping medical practice.

Cardiology as Blueprint: A Lesson for Neuroscience

The history of modern medicine has often been defined by its response to the organs that most visibly threaten human survival. Among these, the Heart has occupied a central position. The ability to understand cardiovascular physiology, recognise disease mechanisms, and develop increasingly sophisticated interventions transformed medicine during the twentieth century. Conditions once considered sudden and irreversible, including myocardial infarction, heart failure, and life-threatening arrhythmias, gradually became preventable or manageable through advances in pharmacology, imaging, surgery, and interventional techniques. For the latter half of the twentieth century, the cardiovascular system was the primary focus of modern clinical medicine. We mapped its electrophysiology with precision, opened blocked coronary arteries using percutaneous interventions, and developed pharmacological therapies that transformed cardiovascular disease from a frequent death sentence into a manageable chronic condition. The discovery of statins, the refinement of coronary bypass surgery, and the widespread implementation of acute coronary syndrome protocols represent a monumental collaborative triumph in clinical science. We learned to stabilize the heart and, in doing so, we bought our patients decades of additional life. However, as medicine advances further, a new frontier is emerging. The focus is gradually shifting from an organ traditionally viewed as the centre of survival to one that defines human existence itself, the Brain. This transition does not represent merely a change from cardiology to neurology; rather, it reflects a deeper evolution in our understanding of human biology. In reality, no organ functions in isolation, and medicine is only beginning to reckon with that truth.

To understand the future of neuroscience, it is instructive to examine how medicine transformed cardiovascular disease. The revolution in cardiology was not the result of a single discovery. It was a systemic shift in how medicine viewed the disease process. Large-scale epidemiological studies, beginning with the Framingham Heart Study, transformed cardiology into a science of predictive risk factors, focusing aggressively on hypertension, dyslipidaemia, and insulin resistance. Cardiology became mechanistic, preventative, and interventionist. It learned to identify vulnerability before catastrophe and to act before the point of irreversibility.

The growing recognition of the heart brain axis illustrates this changing paradigm. Cardiovascular health has long been associated with neurological outcomes through conditions such as stroke, hypertension, vascular disease, and atrial fibrillation. Yet contemporary research has revealed that the relationship between the cardiovascular and nervous systems extends far beyond vascular events. The heart and brain communicate continuously through autonomic pathways, hormonal signals, immune mediators, and metabolic interactions. Disturbances in one system influence the other, creating a biological continuum rather than separate disease categories. This understanding has profound clinical implications. The brain is among the most metabolically demanding organs in the human body, requiring a constant supply of oxygen and nutrients. Even subtle abnormalities in vascular function, inflammation, or metabolic regulation can influence neuronal health long before obvious neurological symptoms emerge. The prevention of cognitive decline, therefore, may begin decades before a patient develops memory impairment. Management of cardiovascular risk factors may ultimately prove to be one of the earliest forms of neuroprotection.

The transformation of neuroscience itself has accelerated this shift. For much of medical history, the brain was studied primarily through anatomy, its regions, pathways, and visible structures. Modern neuroscience has moved far beyond this approach. The brain is now understood as a dynamic network of billions of neurons, supported by complex interactions with glial cells, immune mechanisms, vascular systems, and molecular pathways. The development of advanced imaging techniques, computational neuroscience, and molecular biology has allowed researchers to explore not only where activity occurs in the brain but also how information is processed and how networks adapt or fail. Technologies such as functional magnetic resonance imaging, diffusion imaging, and molecular imaging have provided unprecedented insight into brain organisation. The emergence of connectomics, the study of neural connectivity at large scale, has changed the way scientists conceptualise brain function. Instead of viewing the brain as a collection of isolated regions responsible for individual tasks, neuroscience increasingly recognises it as an integrated communication network in which cognition, memory, emotion, and behaviour arise from interactions among multiple systems.

At the molecular level, the understanding of neurological disease has undergone an equally dramatic transformation. Neurodegenerative disorders, once considered inevitable consequences of ageing, are now recognised as complex biological processes involving genetic vulnerability, abnormal protein handling, mitochondrial dysfunction, altered immune responses, and chronic inflammation. Diseases such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions are no longer viewed through a single pathological lens but as disorders arising from multiple interacting mechanisms.

The Scale of the Neurological Crisis

The numbers are, by any standard, alarming. Neurological disorders are now the leading cause of disability-adjusted life years globally, surpassing cardiovascular disease in this critical metric. Dementia affects more than fifty-five million people worldwide, a figure projected to reach one hundred and fifty million by 2050, driven by ageing populations across Asia, Africa, and Latin America. In India alone, conservative estimates suggest over eight million individuals are currently living with dementia, with the true burden likely considerably higher owing to diagnostic under-recognition in rural and semi-urban settings. Alzheimer's disease, which accounts for approximately sixty to seventy percent of dementia cases, remains without a disease-modifying therapy that is both accessible and unequivocally effective at scale.

One of the most important discoveries in this field has been the changing perception of the brain's immune environment. Microglia, the resident immune cells of the central nervous system, were traditionally regarded as simple protective cells responsible for removing cellular debris. Current research demonstrates a much more sophisticated role. Microglia regulate synaptic connections, respond to injury, influence neuronal survival, and maintain the delicate balance required for normal brain function. However, prolonged or dysregulated activation may contribute to neurodegeneration by promoting chronic inflammation and neuronal injury. This insight has shifted therapeutic strategies. The goal is no longer simply to eliminate abnormal proteins or target a single disease marker. Instead, researchers are increasingly attempting to restore the broader biological environment that allows neurons to remain healthy. This represents a major conceptual shift from treating the consequences of neuronal loss to understanding and modifying the processes that cause neuronal vulnerability.

The challenge of neurodegenerative diseases has become particularly urgent because of global demographic changes. As life expectancy increases, disorders affecting cognition and neurological function are becoming among the greatest healthcare challenges of the modern era. Unlike many acute illnesses, neurodegenerative diseases develop silently over years or decades. By the time clinical symptoms become apparent, significant biological changes may already have occurred. This has intensified the search for early biomarkers capable of identifying disease before irreversible damage develops. Advances in blood-based biomarkers, cerebrospinal fluid analysis, genetic profiling, and digital monitoring are transforming the possibility of early detection. The future of neurology may therefore move away from diagnosing disease only after symptoms appear and toward identifying biological vulnerability before functional decline begins. Such a transformation would represent the true arrival of preventive neurology. Instead of asking only how to treat a patient who has developed dementia or movement disorders, medicine may increasingly ask how to preserve brain health throughout life.

Beyond dementia, the neuropsychiatric burden is equally profound. Depression affects more than three hundred million people globally and is the single leading cause of disability worldwide. Anxiety disorders, affecting a further two hundred and eighty million individuals, are now understood to have neurobiological substrates as measurable and as reproducible as any cardiological biomarker. This issue of PJMHS presents in its 'Recent Medical Advances' section compelling evidence of both: a meta-analysis from the University of California Davis documenting a consistent, transdiagnostic reduction in prefrontal cortical choline across anxiety disorder subtypes, and a landmark multicentre cohort study from Germany demonstrating that high consumption of sugary soft drinks is associated with increased depression risk, mediated by gut microbiome disruption and the gut-brain axis. These are not soft science findings. They are peer-reviewed, biologically grounded, and clinically actionable.

Parkinson's disease, multiple sclerosis, epilepsy, stroke, traumatic brain injury, and the long-term neurological sequelae of SARS-CoV-2 infection collectively account for an economic and human burden that dwarfs most other disease categories combined. The neurological consequences of COVID-19 alone, ranging from cognitive impairment and peripheral neuropathy to encephalitis and cerebrovascular events, have added a new and poorly understood dimension to global brain health that this journal addresses directly in the current issue.

Alzheimer's Disease: A Paradigm in Transition

Nowhere is the transformation of neuroscience more dramatic than in our evolving understanding of Alzheimer's disease. For decades, the dominant framework held that amyloid-beta plaques were the primary initiating event in Alzheimer's pathogenesis, with tau neurofibrillary tangles, neuroinflammation, and synaptic loss following as downstream consequences. This framework guided drug development for more than thirty years and, until recently, produced a sequence of clinical trial failures that left neurologists and patients alike deeply discouraged.

The science is now moving with remarkable speed in several simultaneous directions. A landmark study from Harvard Medical School and Rush University, published in Nature in August 2025 and presented in the 'Recent Medical Advances' section of this issue, has identified lithium deficiency as a potentially fundamental and early event in Alzheimer's pathogenesis. The study demonstrates that amyloid-beta plaques actively sequester endogenous brain lithium, progressively depleting its availability and triggering a downstream cascade characterised by GSK3-beta activation, suppression of Wnt signalling, tau hyperphosphorylation, and microglial pro-inflammatory polarisation. In mouse models, reducing cortical lithium by approximately fifty percent accelerated all hallmarks of Alzheimer's disease, while supplementation with lithium orotate reversed these changes and restored memory. This finding does not displace the amyloid hypothesis; it enriches it, offering a new mechanistic node and a potentially accessible therapeutic target.

Simultaneously, pharmacological enhancement of glymphatic function is emerging as a compelling preventive strategy. The glymphatic system, identified only in 2012, is a brain-wide waste clearance network driven by cerebrospinal fluid flow through astrocytic perivascular channels. It operates predominantly during sleep, removing amyloid-beta, tau, and other metabolic waste products that accumulate during waking hours. Another study demonstrates that gentle cutaneous stimulation of the face and neck can double brain waste clearance through glymphatic mechanisms, offering a non-pharmacological and readily accessible approach to neurodegeneration prevention.

The Metabolic Brain: A Bridge Between Two Volumes

One of the most consequential insights bridging our previous volume on Diabetes and metabolic medicine with this volume on brain health is the emerging concept of cerebral insulin resistance. The brain, which accounts for only two percent of total body weight yet consumes approximately twenty percent of the body's circulating glucose, is exquisitely sensitive to metabolic impairment. When neurons in the hippocampus and prefrontal cortex become resistant to insulin signalling, they lose the energy required to maintain synaptic connections, long-term potentiation, and the molecular machinery of memory consolidation. This framework, sometimes described as Alzheimer's disease as a form of Type 3 Diabetes, has moved from hypothesis to active clinical investigation. Ongoing trials are examining the repurposing of GLP-1 receptor agonists, agents this journal championed extensively in its 2025 diabetes issue, for their neuroprotective and anti-inflammatory properties within the central nervous system. The neurologist of the future will need to be deeply conversant with metabolic medicine, and the endocrinologist with neurological risk. The frontier between these specialties is dissolving, to the benefit of patients and practitioners alike.

Neuroplasticity, the Music-Brain Axis, and the Expanding Boundaries of Neuroscience

One of the most intellectually exhilarating developments in contemporary neuroscience is the systematic dismantling of the once-prevailing view that the adult brain is essentially fixed and immutable. The concept of neuroplasticity, the capacity of the brain to reorganise its structure and function in response to experience, learning, injury, and environment, has moved from theoretical framework to clinical reality with breathtaking speed. This journal has consistently championed this science, and nowhere more distinctively than in its dedicated category: The Music-Brain Axis in the 'Recent Medical Advances' section.

The studies presented in this category in the current issue collectively make a remarkable case. Music training in children not only accelerates reading acquisition through enhanced cortical tracking of speech, but bridges socioeconomic learning gaps that resist conventional pedagogical interventions. Neural resonance theory illuminates the universal biological mechanisms through which rhythm synchronises brain oscillations across individuals, explaining why groove responses to music transcend culture and geography. Acoustic stimulation modulates mechanosensitive gene expression and adipocyte differentiation, suggesting that sound operates as a biological signal at the cellular level. And a landmark multinational cluster-randomised trial, the MIDDEL study conducted across six countries, examines with rigorous methodology, the clinical effectiveness of group music therapy and recreational choir singing for dementia and depression in care home residents, yielding findings that are nuanced, culturally contextualised, and methodologically exemplary.

It is worth noting that the scientific investigation of music as medicine is not without deep historical roots in the Indian tradition. The classical discipline of 'Raga Chikitsa', the therapeutic application of specific ragas through the precise acoustic frequencies and emotional registers encoded within them, has long held that targeted musical exposure can induce measurable physiological states, stimulate parasympathetic dominance, and alleviate neuropsychiatric symptoms. Contemporary functional MRI and quantitative EEG research is beginning to provide a neurobiological vocabulary for what Indian classical musicians and healers have understood intuitively for centuries. That this ancient wisdom and modern neuroscience are converging is not a coincidence. It is a reminder that the brain has always been responsive to beauty, to rhythm, and to the healing power of sound.

Beyond music, this issue presents a study of arresting simplicity and profound implication: spontaneous eye blinks synchronise with musical beats during passive listening, and this synchronisation correlates with white matter microstructure in the left superior longitudinal fasciculus. This finding, published in PLOS Biology, reveals an entirely new dimension of auditory-motor integration operating below the threshold of conscious awareness, with potential implications for understanding timing disorders in Parkinson's disease, ADHD, and developmental coordination disorder.

Artificial Intelligence and the Brain: A Partnership of Extraordinary Promise

Perhaps no development in contemporary neuroscience and clinical neurology carries more transformative potential than the deepening partnership between Artificial Intelligence (AI) and Brain Science. This partnership operates on at least three distinct levels: AI as a tool for understanding brain biology, AI as a clinical diagnostic instrument, and AI as an inspiration for understanding cognition itself.

At the diagnostic level, the evidence presented in the 'Recent Medical Advances' section of this issue is striking. A deep learning model developed at Yale School of Medicine and validated across three independent international cohorts, including the UK Biobank population study of over forty-five thousand participants, detects hypertrophic cardiomyopathy from images of standard twelve-lead ECGs with an AUROC of 0.95 in internal testing and 0.91 in the UK Biobank, using nothing more sophisticated than a photograph of a printed ECG taken on a smartphone. While this study sits within our cardiovascular section, its methodological architecture represents a template for AI-driven neurological diagnostics directly applicable to disorders from epilepsy to dementia.

At the frontier of neural interface technology, this issue presents a proof-of-concept study from the University Miguel Hernandez, Elche, Spain, demonstrating that a bidirectional closed-loop cortical visual prosthesis can accurately predict perceptual thresholds, brightness, and the minimum intertrain interval for separate phosphene perception from simultaneously recorded neural activity in blind human volunteers. This represents a fundamental advance over open-loop stimulation paradigms, establishing for the first time that real-time neural feedback can be used to adaptively optimise stimulation parameters in a human visual cortex implant. The implications for restoring functional vision in individuals blinded by retinal or optic nerve disease are profound.

Beyond diagnostics and therapeutics, AI is transforming our understanding of the brain itself. The magnetically guided stem cell microrobots presented in this issue, steered by external magnetic fields and activated by ultrasound to differentiate into neurons at precise anatomical targets, represent a convergence of robotics, materials science, stem cell biology, and neural engineering that would have been considered premature even a decade ago. That it is now published peer-reviewed science is a measure of how rapidly the boundaries of the possible are moving.

The Gut-Brain Axis: Psychiatry's New Frontier

Among the most consequential conceptual shifts in contemporary neuroscience and psychiatry is the recognition that the brain is not an isolated sovereign but a deeply embedded participant in a vast biological conversation that extends throughout the body. The gut-brain axis, the bidirectional communication network linking the enteric nervous system, the gut microbiome, the immune system, and the central nervous system through vagal, hormonal, and metabolic pathways, has emerged over the past decade as one of the most fertile and clinically relevant territories in all of medicine.

This issue in its 'Recent Medical Advances' section presents two studies that illuminate different dimensions of this axis with considerable force. The German multicentre JAMA Psychiatry cohort study demonstrates that high consumption of sugary soft drinks is associated with significantly increased depression risk. The gut bacterium Eggerthella was identified as a significant mediator, accounting for approximately four percent of the effect on major depressive disorder diagnosis. Women showed a seventeen percent higher risk of depression with high soft drink intake. Separately, a cross-sectional study published in Exploratory Research and Hypothesis in Medicine presents intriguing associational evidence that oral microbiota transmission between intimate partners may contribute to the propagation of depression and anxiety symptoms, with salivary cortisol elevation as a measurable indicator of physiological stress activation in healthy spouses of affected partners.

These studies, taken together, reinforce a vision of psychiatric illness that is simultaneously more biological and more social than the paradigms that preceded them. Depression is not merely a disorder of serotonin or of cognition. It is a disorder of microbial ecology, of metabolic signalling, of inflammatory cascades, and of the extraordinarily intimate biological connections that human beings share with one another. This is psychiatry growing into neuroscience, and neuroscience growing into medicine.

From the Clinic to the Cosmos: The Breadth of This Issue

An Editorial for a journal of this breadth cannot do justice to every study within its pages. What it can do is gesture toward the extraordinary range of scientific inquiry that this issue represents. In our surgical and regenerative medicine category in the 'Recent Medical Advances' section, a bidirectional cortical visual prosthesis restores the possibility of functional vision to the blind. A subretinal photovoltaic implant achieves meaningful visual restoration in geographic atrophy secondary to age-related macular degeneration. In our oncology section, AI-enhanced proteomics detects silent hepatic and pancreatic malignancies at a stage when intervention remains possible, while engineered probiotics and oncolytic viral therapies bring precision immunotherapy into an era of previously unimaginable specificity.

In public health and nutrition, the collapse of the food matrix in ultra-processed foods is shown to impair satiety and metabolism through mechanisms that transcend simple nutrient composition, while a large clinical trial demonstrates that daily multivitamin supplementation is associated with measurable slowing of biological ageing as assessed by epigenetic clock analysis. Asteroid Ryugu has yielded the complete set of nucleobases, sugars, and phosphates necessary for genetic material, suggesting that the molecular precursors of life may be far more widely distributed across the cosmos than previously imagined. And in our maternal health section, thyroid function within the conventional normal range during pregnancy is associated with elevated gestational diabetes risk, a finding with immediate clinical implications for antenatal screening protocols across India and beyond.

A Note on the Cover

The 'Golden Brain' that would grace PJMHS's cover for the entirety of 2026 was conceived not merely as an aesthetic choice but as a statement of editorial intent. It shows a golden human form in anatomical profile, its cranial vault transparent, revealing the brain within in luminous detail. The cerebral cortex, the hippocampus, the limbic circuit, the thalamus, the cerebellum, the brainstem, the descending spinal pathways, all rendered in gold against darkness. It is, simultaneously, a precise anatomical illustration and a meditation on value. Gold does not corrode. It does not diminish. It endures. To render the brain in gold is to assert what every physician, every neuroscientist, every neurologist, every psychiatrist, and every patient living with neurological illness already knows: that the brain is the most precious and the most fragile structure in the known universe, and that its protection, its nourishment, and its restoration are among the highest obligations of medicine.

The transition from heart to brain across the covers of this journal reflects a broader movement in global medicine. It does not signal an abandonment of cardiovascular science, which continues to generate findings of extraordinary clinical importance within these very pages. It signals, rather, an expansion of perspective, a willingness to follow the science wherever it leads, and a recognition that the next great chapter of medicine will be written in the language of neurons, synapses, and the remarkable plasticity of the most extraordinary organ that nature has ever produced.

Closing Reflection

Medicine has always advanced by shifting its gaze. From the gross anatomy of the Renaissance to the Cellular Pathology of Virchow, from the Bacteriological Revolution of Pasteur and Koch to the Molecular Biology of Watson and Crick, from the Genomic Era of the Human Genome Project to the Precision Medicine of today, each great transition has been preceded by a period in which the tools, the concepts, and the courage necessary to see something new have converged. We are living through such a convergence now, and its subject is the brain. The human brain is no longer a dark box beyond the reach of meaningful intervention. The pathways to treatment are being mapped by relentless scientific inquiry. As we navigate this frontier, we must do so with intellectual humility, rigorous clinical standards, and an unwavering commitment to improving patient outcomes.

The Pacific Journal of Medical and Health Sciences enters Volume 11 with the quiet confidence of a publication that has always understood its purpose: to bring the best of global medical science to the clinicians, researchers, educators, and students who need it most, in a form that is rigorous without being forbidding, accessible without being superficial, and always in the service of better medicine and better lives.

The cardiovascular pioneers of the twentieth century gave our patients the gift of time. The mandate of the twenty-first century is to ensure that the minds experiencing that time remain healthy, vibrant, and profoundly human. The heart introduced medicine to the power of intervention. The brain now invites medicine to explore the possibilities of preservation, restoration, and renewal. The future of healthcare will not simply be about adding years to life. It will be about protecting the very capabilities that make those years meaningful.

The 'Golden Brain' on our cover is not a boast. It is a promise. We invite you to read, to question, to debate, and above all, to be inspired. The next frontier of medicine is before us. It is golden, it is complex, it is fragile, and of course, it is magnificent.

R. Bangur

(Ravindra Bangar)
Editor